The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
Abstract This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-20056-3 |
| _version_ | 1797996181574385664 |
|---|---|
| author | Kadriye Bir Yücel Emre Yekedüz Serdar Karakaya Deniz Tural İsmail Ertürk Cihan Erol Özlem Ercelep Nihan Şentürk Öztaş Çağatay Arslan Gökhan Uçar Ahmet Küçükarda Özlem Nuray Sever Saadettin Kılıçkap Orçun Can Satı Coşkun Yazgan Berna Öksüzoğlu Nuri Karadurmuş Mehmet Ali Şendur Yüksel Ürün |
| author_facet | Kadriye Bir Yücel Emre Yekedüz Serdar Karakaya Deniz Tural İsmail Ertürk Cihan Erol Özlem Ercelep Nihan Şentürk Öztaş Çağatay Arslan Gökhan Uçar Ahmet Küçükarda Özlem Nuray Sever Saadettin Kılıçkap Orçun Can Satı Coşkun Yazgan Berna Öksüzoğlu Nuri Karadurmuş Mehmet Ali Şendur Yüksel Ürün |
| author_sort | Kadriye Bir Yücel |
| collection | DOAJ |
| description | Abstract This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx109/L) x platelet (cellsx109/L)] / lymphocyte (cellsx109/L).All patients were classified into SII-high and SII-low groups based on the cut-off value of SII at 756, which was the median SII level of our study group. The minimal follow-up duration was 10 months in all cohorts. The median age of patients was 60 (interquartile range (IQR):53–67) years. Three out of four patients were male. The majority of patients (85.7%) had clear cell histology, and sarcomatoid differentiation was observed in 16.9% of all patients. There were 311 and 310 patients in the SII-low and SII-high groups, respectively. In general, baseline characteristics were similar in each group. However, the rate of patients treated with sunitinib (63.3% vs. 49.0%, p < 0.001) and those who underwent nephrectomy (83.6% vs. 64.2%, p < 0.001) was higher in the SII-low group than in the SII-high group. On the other hand, patients with the IMDC poorrisk (31.6% vs. 8.0%, p < 0.001), those with bone (51.8% vs. 32.2%, p < 0.001) or central nervous system (12.9% vs. 5.8%, p = 0.026) metastasis, and those with Eastern Cooperative Oncology Group(ECOG) 2–4 performance score (28.1% vs.17.7%, p = 0.002) were more common in the SII-high group than in the SII-low group. The median overall survival (OS) was longer in the SII-low group than in the SII-high group (34.6 months vs. 14.5 months, p < 0.001). Similarly, the median progression-free survival (PFS) was longer in the SII-low group than in the SII-high group (18.0 months vs. 7.7 months, p < 0.001).In multivariableanalysis, SII was an independent prognostic factor for OS (hazard ratio (HR):1.39, 95% confidence interval (CI):1.05–1.85, p = 0.01) and PFS (HR:1.60, 95% CI:1.24–2.05, p < 0.001).Pre-treatment level of high SII might be considered a predictor of poor prognosisin patients with mRCC treated with TKIs. |
| first_indexed | 2024-04-11T10:13:33Z |
| format | Article |
| id | doaj.art-ff731989e9c14a97850334af8794a507 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T10:13:33Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-ff731989e9c14a97850334af8794a5072022-12-22T04:30:03ZengNature PortfolioScientific Reports2045-23222022-10-011211910.1038/s41598-022-20056-3The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitorsKadriye Bir Yücel0Emre Yekedüz1Serdar Karakaya2Deniz Tural3İsmail Ertürk4Cihan Erol5Özlem Ercelep6Nihan Şentürk Öztaş7Çağatay Arslan8Gökhan Uçar9Ahmet Küçükarda10Özlem Nuray Sever11Saadettin Kılıçkap12Orçun Can13Satı Coşkun Yazgan14Berna Öksüzoğlu15Nuri Karadurmuş16Mehmet Ali Şendur17Yüksel Ürün18Department of Internal Medicine, Faculty of Medicine, Ankara UniversityDepartment of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara UniversityMedical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health SciencesDepartment of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, University of Health SciencesDepartment of Medical Oncology, Gülhane Education and Research Hospital, University of Health SciencesDepartment of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt UniversityDepartment of Medical Oncology, Faculty of Medicine, Marmara UniversityDivision of Medical Oncology, Cerrahpaşa Faculty of Medicine, İstanbul University-CerrahpaşaDepartment of Medical Oncology, Faculty of Medicine, İzmir University of EconomicsDepartment of Medical Oncology, Ankara City Hospital, University of Health SciencesDepartment of Medical Oncology, Faculty of Medicine, Trakya UniversityDepartment of Medical Oncology, Faculty of Medicine, Gaziantep UniversityDepartment of Medical Oncology, Faculty of Medicine, Hacettepe UniversityDepartment of Medical Oncology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health SciencesDepartment of Internal Medicine, Faculty of Medicine, Ankara UniversityMedical Oncology Department, Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, University of Health SciencesDepartment of Medical Oncology, Gülhane Education and Research Hospital, University of Health SciencesDepartment of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt UniversityDepartment of Medical Oncology, Faculty of Medicine, Cebeci Hospital, Ankara UniversityAbstract This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx109/L) x platelet (cellsx109/L)] / lymphocyte (cellsx109/L).All patients were classified into SII-high and SII-low groups based on the cut-off value of SII at 756, which was the median SII level of our study group. The minimal follow-up duration was 10 months in all cohorts. The median age of patients was 60 (interquartile range (IQR):53–67) years. Three out of four patients were male. The majority of patients (85.7%) had clear cell histology, and sarcomatoid differentiation was observed in 16.9% of all patients. There were 311 and 310 patients in the SII-low and SII-high groups, respectively. In general, baseline characteristics were similar in each group. However, the rate of patients treated with sunitinib (63.3% vs. 49.0%, p < 0.001) and those who underwent nephrectomy (83.6% vs. 64.2%, p < 0.001) was higher in the SII-low group than in the SII-high group. On the other hand, patients with the IMDC poorrisk (31.6% vs. 8.0%, p < 0.001), those with bone (51.8% vs. 32.2%, p < 0.001) or central nervous system (12.9% vs. 5.8%, p = 0.026) metastasis, and those with Eastern Cooperative Oncology Group(ECOG) 2–4 performance score (28.1% vs.17.7%, p = 0.002) were more common in the SII-high group than in the SII-low group. The median overall survival (OS) was longer in the SII-low group than in the SII-high group (34.6 months vs. 14.5 months, p < 0.001). Similarly, the median progression-free survival (PFS) was longer in the SII-low group than in the SII-high group (18.0 months vs. 7.7 months, p < 0.001).In multivariableanalysis, SII was an independent prognostic factor for OS (hazard ratio (HR):1.39, 95% confidence interval (CI):1.05–1.85, p = 0.01) and PFS (HR:1.60, 95% CI:1.24–2.05, p < 0.001).Pre-treatment level of high SII might be considered a predictor of poor prognosisin patients with mRCC treated with TKIs.https://doi.org/10.1038/s41598-022-20056-3 |
| spellingShingle | Kadriye Bir Yücel Emre Yekedüz Serdar Karakaya Deniz Tural İsmail Ertürk Cihan Erol Özlem Ercelep Nihan Şentürk Öztaş Çağatay Arslan Gökhan Uçar Ahmet Küçükarda Özlem Nuray Sever Saadettin Kılıçkap Orçun Can Satı Coşkun Yazgan Berna Öksüzoğlu Nuri Karadurmuş Mehmet Ali Şendur Yüksel Ürün The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors Scientific Reports |
| title | The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| title_full | The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| title_fullStr | The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| title_full_unstemmed | The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| title_short | The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| title_sort | relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors |
| url | https://doi.org/10.1038/s41598-022-20056-3 |
| work_keys_str_mv | AT kadriyebiryucel therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT emreyekeduz therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT serdarkarakaya therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT deniztural therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ismailerturk therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT cihanerol therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ozlemercelep therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT nihansenturkoztas therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT cagatayarslan therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT gokhanucar therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ahmetkucukarda therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ozlemnuraysever therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT saadettinkılıckap therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT orcuncan therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT satıcoskunyazgan therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT bernaoksuzoglu therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT nurikaradurmus therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT mehmetalisendur therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT yukselurun therelationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT kadriyebiryucel relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT emreyekeduz relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT serdarkarakaya relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT deniztural relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ismailerturk relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT cihanerol relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ozlemercelep relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT nihansenturkoztas relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT cagatayarslan relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT gokhanucar relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ahmetkucukarda relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT ozlemnuraysever relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT saadettinkılıckap relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT orcuncan relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT satıcoskunyazgan relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT bernaoksuzoglu relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT nurikaradurmus relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT mehmetalisendur relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors AT yukselurun relationshipbetweensystemicimmuneinflammationindexandsurvivalinpatientswithmetastaticrenalcellcarcinomatreatedwithtyrosinekinaseinhibitors |